Karl C. Kronmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karl C. Kronmann has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
- Kwadwo Ansah Koram
Epidemiology Department, Noguchi Memorial Institute for Medical Research, University of Ghana
4 shared publications - James Odame Aboagye
Noguchi Memorial Institute of Medical Research, University of Ghana, Legon, Ghana
3 shared publications - Nancy Odurowah Duah-Quashie
Department of Epidemiology, Noguchi Memorial Institute for Medical Research, University of Ghana
3 shared publications - Prince Godfred Agbenohevi
37 Military Hospital, Accra, Ghana
3 shared publications - William Kwabena Ampofo
Department of Virology, Noguchi Memorial Institute for Medical Research, Legon, Accra, Ghana.
3 shared publications Anuradha Ganesan
Infectious Disease Clinical Research Program, Department of Preventive Medicine, Uniformed Services University of the Health Sciences, Bethesda, USA
2 shared publications
Latest Publications
- Open Access
- 12 May 2021
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 18 (1) , 1-6
Association between depression and HIV treatment outcomes in a US military population with HIV infection
Background: Depression is common among HIV-infected individuals and may contribute to suboptimal adherence to antiretroviral therapy (ART) and subsequent inability to attain viral load (VL) suppression. We evaluated associations between depression, self-reported adherence, and longitudinal HIV treatment outcomes in US Military HIV Natural History Study (NHS) participants with and without depression. Methods: Male NHS participants with available ICD-9 data for mental health diagnoses, Center for Epidemiological Studies Depression (CES-D) measures, and self-reported adherence (SRA) were included. ART use was defined as ART initiation between 2006 and 2010, with follow-up through 2015. SRA was defined as taking 95% of ART doses and continuous ART was defined as longitudinal ART use with gaps < 30 days. Continuous VL suppression was defined as maintaining VLs < 200 c/mL on ART. To analyse the association between depression and HIV treatment outcomes, latent class analysis was used to create classes of depression trajectories: low depression (LD), recent onset depression (ROD) and high Depression (HD). Results: Participants had a mean age of 32 (± 8.3) years at HIV diagnosis, and similar proportions were Caucasian (44.3%) or African American (40.8%). Overall, older participants at HIV diagnosis had greater odds of having 95% self-reported adherence (OR 1.06, 95% CI 1.02–1.12), and African Americans had lower odds (OR 0.41, 95% CI 0.22–0.76) compared to Caucasians (OR 1.49, 95% CI 0.52–4.28). However, there was no difference in SRA by depression trajectory. Participants with HD had an increased odds of taking ART continuously (OR 1.75, 95% CI 0.99–3.09), and those with ROD had significantly higher odds of virologic failure (OR 0.58, 95% CI 0.38–0.91). Conclusions: Although there was no observed association between depression and SRA, participants with ROD had lower odds of attaining the HIV treatment goal of VL suppression. Continued efforts to identify and aggressively manage mental health disorders is important to success along the HIV care continuum.
- 12 May 2021
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 18 (1) , 1-6
Open AccessAssociation between depression and HIV treatment outcomes in a US military population with HIV infection
Background: Depression is common among HIV-infected individuals and may contribute to suboptimal adherence to antiretroviral therapy (ART) and subsequent inability to attain viral load (VL) suppression. We evaluated associations between depression, self-reported adherence, and longitudinal HIV treatment outcomes in US Military HIV Natural History Study (NHS) participants with and without depression. Methods: Male NHS participants with available ICD-9 data for mental health diagnoses, Center for Epidemiological Studies Depression (CES-D) measures, and self-reported adherence (SRA) were included. ART use was defined as ART initiation between 2006 and 2010, with follow-up through 2015. SRA was defined as taking 95% of ART doses and continuous ART was defined as longitudinal ART use with gaps < 30 days. Continuous VL suppression was defined as maintaining VLs < 200 c/mL on ART. To analyse the association between depression and HIV treatment outcomes, latent class analysis was used to create classes of depression trajectories: low depression (LD), recent onset depression (ROD) and high Depression (HD). Results: Participants had a mean age of 32 (± 8.3) years at HIV diagnosis, and similar proportions were Caucasian (44.3%) or African American (40.8%). Overall, older participants at HIV diagnosis had greater odds of having 95% self-reported adherence (OR 1.06, 95% CI 1.02–1.12), and African Americans had lower odds (OR 0.41, 95% CI 0.22–0.76) compared to Caucasians (OR 1.49, 95% CI 0.52–4.28). However, there was no difference in SRA by depression trajectory. Participants with HD had an increased odds of taking ART continuously (OR 1.75, 95% CI 0.99–3.09), and those with ROD had significantly higher odds of virologic failure (OR 0.58, 95% CI 0.38–0.91). Conclusions: Although there was no observed association between depression and SRA, participants with ROD had lower odds of attaining the HIV treatment goal of VL suppression. Continued efforts to identify and aggressively manage mental health disorders is important to success along the HIV care continuum.
- Open Access
- 6 February 2019
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 100 (2) , 233-234
Plasmodium malariae—Repeat Light Microscopy when Molecular Testing is Not Available
- 6 February 2019
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 100 (2) , 233-234
Open AccessPlasmodium malariae—Repeat Light Microscopy when Molecular Testing is Not Available
- Open Access
- 1 November 2018
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 183 (11-12) , 252-257
Disaster Response to Puerto Rico: An Internal Medicine Humanitarian Response Aboard the USNS COMFORT
The USNS COMFORT (T-AH 20) hospital ship supports three missions: medical care of the warfighter, scheduled humanitarian assistance, and disaster response. One of the COMFORT’s most impactful disaster response missions occurred in 2010 when the ship deployed in support of Operation Unified Response after a 7.0 magnitude earthquake devastated Haiti. Amundson et al detailed their experience and the capabilities of the 1,000-bed hospital ship.1 On September 20, 2017, Hurricane Maria struck the territory of Puerto Rico as a Category 4 storm, resulting in a humanitarian crisis. On September 29, with as short as 24-hour notice, COMFORT crew and an additional personnel attachment deployed to provide assistance. Hospital ships provide humanitarian support during disaster relief missions similar to terrestrial resources such as Army Combat Support Hospitals (CSHs) and Air Force Expeditionary Medical Support Health Response Teams (EMEDS), both of which were also deployed to Puerto Rico. These mobile healthcare venues’ missions are to fill any gaps in medical care while the host nation recovers.
- 1 November 2018
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 183 (11-12) , 252-257
Open AccessDisaster Response to Puerto Rico: An Internal Medicine Humanitarian Response Aboard the USNS COMFORT
The USNS COMFORT (T-AH 20) hospital ship supports three missions: medical care of the warfighter, scheduled humanitarian assistance, and disaster response. One of the COMFORT’s most impactful disaster response missions occurred in 2010 when the ship deployed in support of Operation Unified Response after a 7.0 magnitude earthquake devastated Haiti. Amundson et al detailed their experience and the capabilities of the 1,000-bed hospital ship.1 On September 20, 2017, Hurricane Maria struck the territory of Puerto Rico as a Category 4 storm, resulting in a humanitarian crisis. On September 29, with as short as 24-hour notice, COMFORT crew and an additional personnel attachment deployed to provide assistance. Hospital ships provide humanitarian support during disaster relief missions similar to terrestrial resources such as Army Combat Support Hospitals (CSHs) and Air Force Expeditionary Medical Support Health Response Teams (EMEDS), both of which were also deployed to Puerto Rico. These mobile healthcare venues’ missions are to fill any gaps in medical care while the host nation recovers.
- 1 August 2018
- Vol. 25 (8) , 5-7
Brief report: Pre- and post-deployment prevalence of Staphylococcus aureus colonization among U.S. Navy submariners.
- 1 August 2018
- Vol. 25 (8) , 5-7
Brief report: Pre- and post-deployment prevalence of Staphylococcus aureus colonization among U.S. Navy submariners.
- Open Access
- 17 July 2017
- Published by Springer Nature in BMC Research Notes
- Vol. 10 (1) , 1-7
Prevalence of enteric infections among hospitalized patients in two referral hospitals in Ghana
Diarrhea is an important cause of morbidity and mortality worldwide. In Africa and Ghana in particular, it is estimated to contribute directly to 19 and 25% of pediatric mortality among children under 5 years, respectively. Surveillance for hospitalized acute diarrheal illness was initiated in November 2010 through October 2012 in a referral hospital in southern Ghana, and a teaching hospital in northern Ghana. Consenting hospitalized patients who met a standardized case definition for acute diarrheal illness provided demographic and epidemiologic data. Stool samples were collected and tested by culture for bacteria and by enzyme immunoassays for a panel of viruses and parasites. A total of 429 patients were enrolled; 216 (50.3%) were under 5 years, and 221 (51.5%) were females. Stool samples were received from 153 patients. Culture isolates included Shigella sp., Salmonella spp., Plesiomonas sp. and Vibrio cholerae. Of 147 samples tested for viruses, 41 (27.9%) were positive for rotaviruses, 11 (7.5%) for astroviruses, 10 (6.8%) for noroviruses, and 8 (5.4%) for adenoviruses. Of 116 samples tested for parasitic infections; 4 (3.4%) were positive for Cryptosporidium sp. and 3 (2.6%) for Giardia lamblia. Of the enrolled patients, 78.8% had taken antibiotics prior to sample collection. Diarrheal pathogens were identified across all ages, however, predominantly (81%) in the children under 5 years of age. This study also detected high antibiotic use which has the potential of increasing antibiotic resistance. The most common enteric pathogen detected (49.4%) was rotavirus.
- 17 July 2017
- Published by Springer Nature in BMC Research Notes
- Vol. 10 (1) , 1-7
Open AccessPrevalence of enteric infections among hospitalized patients in two referral hospitals in Ghana
Diarrhea is an important cause of morbidity and mortality worldwide. In Africa and Ghana in particular, it is estimated to contribute directly to 19 and 25% of pediatric mortality among children under 5 years, respectively. Surveillance for hospitalized acute diarrheal illness was initiated in November 2010 through October 2012 in a referral hospital in southern Ghana, and a teaching hospital in northern Ghana. Consenting hospitalized patients who met a standardized case definition for acute diarrheal illness provided demographic and epidemiologic data. Stool samples were collected and tested by culture for bacteria and by enzyme immunoassays for a panel of viruses and parasites. A total of 429 patients were enrolled; 216 (50.3%) were under 5 years, and 221 (51.5%) were females. Stool samples were received from 153 patients. Culture isolates included Shigella sp., Salmonella spp., Plesiomonas sp. and Vibrio cholerae. Of 147 samples tested for viruses, 41 (27.9%) were positive for rotaviruses, 11 (7.5%) for astroviruses, 10 (6.8%) for noroviruses, and 8 (5.4%) for adenoviruses. Of 116 samples tested for parasitic infections; 4 (3.4%) were positive for Cryptosporidium sp. and 3 (2.6%) for Giardia lamblia. Of the enrolled patients, 78.8% had taken antibiotics prior to sample collection. Diarrheal pathogens were identified across all ages, however, predominantly (81%) in the children under 5 years of age. This study also detected high antibiotic use which has the potential of increasing antibiotic resistance. The most common enteric pathogen detected (49.4%) was rotavirus.
- Open Access
- 19 September 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (9) , e0163066
Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults: A Phase 1, Double-Blinded Placebo Controlled Dosage Escalation Study
The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine antigen, EBA-175 RII-NG adjuvanted with aluminium phosphate to be safe, immunogenic and capable of inducing biologically active antibodies that can inhibit parasite growth in vitro. The aim of the current study was to assess the safety and immunogenicity of this vaccine in malaria exposed semi-immune healthy adults living in a malaria endemic country, Ghana. In this double-blinded, placebo controlled, dose escalation phase I trial, eighteen subjects per group received ascending dose concentrations (5 μg, 20 μg or 80 μg) of the vaccine intramuscularly at 0, 1 and 6 months, while 6 subjects received placebo (normal saline). The primary end point was the number of subjects experiencing Grade 3 systemic or local adverse events within 14 days post-vaccination. Serious adverse events were assessed throughout the study period. Blood samples for immunological analyses were collected at days 0, 14, 28, 42, 180 and 194. A total of 52 subjects received three doses of the vaccine in the respective groups. No serious adverse events were reported. The majority of all adverse events reported were mild to moderate in severity, with local pain and tenderness being the most common. All adverse events, irrespective of severity, resolved without any sequelae. Subjects who received any of the EBA-175 RII-NG doses had high immunoglobulin G levels which moderately inhibited P. falciparum growth in vitro, compared to those in the placebo group. In conclusion, the EBA-175 RII-NG vaccine was safe, well tolerated and immunogenic in malaria semi-immune Ghanaian adults. Its further development is recommended. ClinicalTrials.gov. Identifier: NCT01026246
- 19 September 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (9) , e0163066
Open AccessSafety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults: A Phase 1, Double-Blinded Placebo Controlled Dosage Escalation Study
The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine antigen, EBA-175 RII-NG adjuvanted with aluminium phosphate to be safe, immunogenic and capable of inducing biologically active antibodies that can inhibit parasite growth in vitro. The aim of the current study was to assess the safety and immunogenicity of this vaccine in malaria exposed semi-immune healthy adults living in a malaria endemic country, Ghana. In this double-blinded, placebo controlled, dose escalation phase I trial, eighteen subjects per group received ascending dose concentrations (5 μg, 20 μg or 80 μg) of the vaccine intramuscularly at 0, 1 and 6 months, while 6 subjects received placebo (normal saline). The primary end point was the number of subjects experiencing Grade 3 systemic or local adverse events within 14 days post-vaccination. Serious adverse events were assessed throughout the study period. Blood samples for immunological analyses were collected at days 0, 14, 28, 42, 180 and 194. A total of 52 subjects received three doses of the vaccine in the respective groups. No serious adverse events were reported. The majority of all adverse events reported were mild to moderate in severity, with local pain and tenderness being the most common. All adverse events, irrespective of severity, resolved without any sequelae. Subjects who received any of the EBA-175 RII-NG doses had high immunoglobulin G levels which moderately inhibited P. falciparum growth in vitro, compared to those in the placebo group. In conclusion, the EBA-175 RII-NG vaccine was safe, well tolerated and immunogenic in malaria semi-immune Ghanaian adults. Its further development is recommended. ClinicalTrials.gov. Identifier: NCT01026246
- 11 September 2016
- p. 29-37
Honey Bee Swarms Aboard the USNS Comfort: Recommendations for Sting Prevention, Swarm Removal, and Medical Readiness on Military Ships.
The article provides observations of multiple honey bee (Apis mellifera) swarms aboard the USNS Comfort (TAH-20) during the Continuing Promise 2015 mission. A brief overview of swarming biology is given along with control/removal recommendations to reduce sting exposures. The observations suggest that preventive medicine personnel should provide adequate risk communications about the potential occurrence of bee swarms aboard military ships, and medical department personnel should be prepared for the possibility of treating of multiple sting exposures, especially in the Southern Command Area of Operations where the Africanized genotype of A mellifera is common.
- 11 September 2016
- p. 29-37
Honey Bee Swarms Aboard the USNS Comfort: Recommendations for Sting Prevention, Swarm Removal, and Medical Readiness on Military Ships.
The article provides observations of multiple honey bee (Apis mellifera) swarms aboard the USNS Comfort (TAH-20) during the Continuing Promise 2015 mission. A brief overview of swarming biology is given along with control/removal recommendations to reduce sting exposures. The observations suggest that preventive medicine personnel should provide adequate risk communications about the potential occurrence of bee swarms aboard military ships, and medical department personnel should be prepared for the possibility of treating of multiple sting exposures, especially in the Southern Command Area of Operations where the Africanized genotype of A mellifera is common.
- Open Access
- 1 May 2016
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 23 (5) , taw043
A comparison of compliance rates with anti-vectorial protective measures during travel to regions with dengue or chikungunya activity, and regions endemic forPlasmodium falciparummalaria
Background. There is limited information on compliance rates with anti-vectorial protective measures (AVPMs) during travel to countries with risk of dengue and chikungunya. We evaluated differences in mosquito exposures, and factors associated with AVPM compliance in travellers going to countries where the principal mosquito-borne infectious disease threat is falciparum malaria and those where risk of dengue or chikungunya predominates. Methods. Department of Defence beneficiaries with planned travel to regions where the predominant mosquito-borne infection is falciparum malaria, and those with predominantly dengue or chikungunya risk, were included. Regions were divided into three groups: ‘high-risk falciparum malaria’, ‘low-risk falciparum malaria’ and ‘chikungunya/dengue risk’. Demographics, trip characteristics, arthropod exposure and AVPM compliance were captured using pre- and post-travel surveys. Skin repellent compliance was defined as self-reported use, categorized as ‘often/every day’. A logistic regression model was used to estimate factors associated with AVPM compliance. Results. 183 (9%), 185 (9%) and 149 (7%) travelled to high and low falciparum malaria risk regions, and chikungunya/dengue risk regions, respectively. Overall, 53% (95% CI: 48–57%) and 16% (95% CI: 12–19%) were compliant with repellent use on skin and clothing, respectively. Daytime bites were reported more frequently in chikungunya/dengue risk regions than high malaria risk regions (37% vs. 10%), while night time bites were frequently in high malaria risk regions (53% vs 20%; P < 0.001). Compliance with skin repellents was associated with female gender [RR: 1.54 (95% CI: 1.05–2.28)], observing mosquitoes during travel [RR: 2.77 (95% CI: 1.76–4.36)] and travel during the rainy season [RR: 2.45 (95% CI: 1.66–3.71)]). Conclusions. Poor AVPM compliance was observed in the overall cohort. Compliance with skin repellent use was associated with female gender, observing mosquitoes and travelling during the rainy season, and was not associated with the risk of malaria or chikungunya/dengue at the travel destination.
- 1 May 2016
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 23 (5) , taw043
Open AccessA comparison of compliance rates with anti-vectorial protective measures during travel to regions with dengue or chikungunya activity, and regions endemic forPlasmodium falciparummalaria
Background. There is limited information on compliance rates with anti-vectorial protective measures (AVPMs) during travel to countries with risk of dengue and chikungunya. We evaluated differences in mosquito exposures, and factors associated with AVPM compliance in travellers going to countries where the principal mosquito-borne infectious disease threat is falciparum malaria and those where risk of dengue or chikungunya predominates. Methods. Department of Defence beneficiaries with planned travel to regions where the predominant mosquito-borne infection is falciparum malaria, and those with predominantly dengue or chikungunya risk, were included. Regions were divided into three groups: ‘high-risk falciparum malaria’, ‘low-risk falciparum malaria’ and ‘chikungunya/dengue risk’. Demographics, trip characteristics, arthropod exposure and AVPM compliance were captured using pre- and post-travel surveys. Skin repellent compliance was defined as self-reported use, categorized as ‘often/every day’. A logistic regression model was used to estimate factors associated with AVPM compliance. Results. 183 (9%), 185 (9%) and 149 (7%) travelled to high and low falciparum malaria risk regions, and chikungunya/dengue risk regions, respectively. Overall, 53% (95% CI: 48–57%) and 16% (95% CI: 12–19%) were compliant with repellent use on skin and clothing, respectively. Daytime bites were reported more frequently in chikungunya/dengue risk regions than high malaria risk regions (37% vs. 10%), while night time bites were frequently in high malaria risk regions (53% vs 20%; P < 0.001). Compliance with skin repellents was associated with female gender [RR: 1.54 (95% CI: 1.05–2.28)], observing mosquitoes during travel [RR: 2.77 (95% CI: 1.76–4.36)] and travel during the rainy season [RR: 2.45 (95% CI: 1.66–3.71)]). Conclusions. Poor AVPM compliance was observed in the overall cohort. Compliance with skin repellent use was associated with female gender, observing mosquitoes and travelling during the rainy season, and was not associated with the risk of malaria or chikungunya/dengue at the travel destination.
- Open Access
- 23 January 2015
- Published by Springer Nature in BMC Research Notes
- Vol. 8 (1) , 14
Biosecurity measures to reduce influenza infections in military barracks in Ghana
- 23 January 2015
- Published by Springer Nature in BMC Research Notes
- Vol. 8 (1) , 14
Open AccessBiosecurity measures to reduce influenza infections in military barracks in Ghana
- Open Access
- 17 December 2013
- Published by Springer Nature in Malaria Journal
- Vol. 12 (1) , 450
A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs
Based on report of declining efficacy of chloroquine, Ghana shifted to the use of artemisinin-based combination therapy (ACT) in 2005 as the first-line anti-malarial drug. Since then, there has not been any major evaluation of the efficacy of anti-malarial drugs in Ghana in vitro. The sensitivity of Ghanaian Plasmodium falciparum isolates to anti-malarial drugs was, therefore, assessed and the data compared with that obtained prior to the change in the malaria treatment policy.
- 17 December 2013
- Published by Springer Nature in Malaria Journal
- Vol. 12 (1) , 450
Open AccessA SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs
Based on report of declining efficacy of chloroquine, Ghana shifted to the use of artemisinin-based combination therapy (ACT) in 2005 as the first-line anti-malarial drug. Since then, there has not been any major evaluation of the efficacy of anti-malarial drugs in Ghana in vitro. The sensitivity of Ghanaian Plasmodium falciparum isolates to anti-malarial drugs was, therefore, assessed and the data compared with that obtained prior to the change in the malaria treatment policy.